Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology.
The lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, which works by controlling bacterial infections of airways damaged by toxins, recently completed a Phase 2b clinical trial for Chronic Obstructive Pulmonary Disease (COPD) where the immunotherapeutic did not meet both primary and secondary pre-selected endpoints for the patient group as a whole. However, post hoc analysis showed that the immunotherapeutic was effective in patients under the age of 65. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets.
Bioxyne also makes and sells a range of probiotic products.